occult cancer
Recently Published Documents


TOTAL DOCUMENTS

198
(FIVE YEARS 42)

H-INDEX

26
(FIVE YEARS 3)

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Michael Brun Andersen ◽  
Dyveke Ebbesen ◽  
Jesper Thygesen ◽  
Matthijs Kruis ◽  
Qing Gu ◽  
...  

Abstract Background Based on prior studies spectral CT has shown a higher sensitivity for malignant lesions than conventional CT at the cost of lower specificity. For the radiologists, it also offers a higher degree of certainty in the diagnosis of benign lesions. The objective of this study was to evaluate the economic impact of spectral CT in patients suspected of occult cancer in a medical center in Denmark. Methods This study was a secondary analysis using de-identified data from a prospective study of patients receiving a contrast-enhanced spectral CT scan. Based on suggested follow-up examinations on both spectral CT and contrast-enhanced CT, costs from a payer’s perspective were determined using unit costs obtained from national databases. Results The dataset contained 400 patients. Overall, 203 follow-up procedures were eliminated based on spectral data reading. The largest reduction in suggested follow-up procedures was found for the kidney (83%), followed by the liver (66%), adrenal glands (60%), and pancreas (42%). The total estimated costs for suggested follow-up procedures based on spectral data reading were €155,219, 25.2% (€52,384) less than that of conventional CT reading. Conclusion Our results provide support for spectral body imaging as an advanced imaging modality for suspected occult cancer. A substantial number of follow-up diagnostic procedures could be eliminated based on spectral data reading, which would result in significant cost savings.


2021 ◽  
pp. 1358863X2110349
Author(s):  
Salma Adham ◽  
Guillaume Armengol ◽  
Nicole Cailleux-Talbot ◽  
Hervé Levesque ◽  
Ygal Benhamou ◽  
...  

Author(s):  
Hanne Skille ◽  
Benedikte Paulsen ◽  
Kristian Hveem ◽  
Marianne T. Severinsen ◽  
Maiken E. Gabrielsen ◽  
...  

2021 ◽  
Vol 200 ◽  
pp. S73
Author(s):  
S.H. Okholm ◽  
D. Nagy ◽  
D.K. Farkas ◽  
C.H. Fuglsang ◽  
F.S. Troelsen ◽  
...  

2021 ◽  
Vol 200 ◽  
pp. S25
Author(s):  
A.D. Kjaergaard ◽  
D. Nagy ◽  
C.F. Christiansen ◽  
F.S. Troelsen ◽  
K. Farkas ◽  
...  

2021 ◽  
Vol 200 ◽  
pp. S79-S80
Author(s):  
C. Thålin ◽  
A. Rosell ◽  
L. Gabrielsson ◽  
M. Månsson ◽  
K. Aguilera ◽  
...  

2021 ◽  
Vol 200 ◽  
pp. S78-S79
Author(s):  
S. Marín Romero ◽  
V. Sánchez López ◽  
A. Dorado Elias ◽  
E. Arellano Orden ◽  
T. Elias Hernández ◽  
...  

2021 ◽  
Vol 41 (01) ◽  
pp. 042-047
Author(s):  
Marc Blondon

AbstractActive cancer causes approximately 25% of all acute events of venous thromboembolism (VTE). While most of the cancer diagnoses are known or clinically apparent at the time of VTE, care providers and patients may be worried about the 3 to 8% risk of occult cancer occurring in the year after VTE. Several studies have compared limited to extensive cancer screening after acute VTE, especially with the addition of abdominal computed tomography (CT) or whole-body PET-CT, with the hope to shorten the time to cancer diagnosis and lead to less advanced cancer stages. These studies have not shown improved clinical outcomes with an extensive screening, and have led to current recommendations of limited screening for cancer in patients with acute VTE, including unprovoked cases. Several risk assessment models have been developed to identify patients at greatest risk of occult cancer, however, with low discriminative performances and no current clinical usefulness. Some clinical situations may empirically deserve a more thorough cancer screening, such as unprovoked upper extremity deep vein thrombosis (DVT), bilateral leg DVT, descending leg DVT, or recurrent VTE during anticoagulation.


Sign in / Sign up

Export Citation Format

Share Document